References I-21

1. Trastuzumab (Herceptin®) for injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 11/2018.

2. Tse Hui L, Soon Tiong Lim A, Aye Aye T, et al. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer. Archives of Pathology & Laboratory Medicine. 2016;140(2):140-147.

3. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: breast cancer, version 1.2016.

4. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers, version 3.2015.

5. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: nonsmall cell lung cancer, version 4.2016.

6. Rugo H, Barve A, Pennella E, et al. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA. 2017;317(1):37-47.

7. Denduluri N, Somerfield M, Wolff A. Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary. Journal Of Oncology Practice. May 2016;12(5):485- 488.

8. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: breast cancer, version 2.2017.

9. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers, version 1.2017.

10. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: nonsmall cell lung cancer, version 5.2017. 11. Herzuma (trastuzumab-pkrb) for injection, for intravenous use [package insert]. Teva Pharmaceuticals USA, Inc. North Wales, PA. Revised 06/2019.

12. Ogivri (trastuzumab-dkst) for injection, for intravenous use [package insert]. Mylan. Rockford, IL.. Revised 11/2019.

13. Ontruzant (trastuzumab-dttb) for injection, for intravenous use [package insert]. Merck & Co., Inc. Whitehouse Station, NJ. Revised 03/2020.

14. Trazimera (trastuzumab-qyyp) injection, for intravenous use [package insert]. Pfizer Inc. New York, NY. Revised 01/2020.

15. Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use [package insert]. Genentech, Inc. San Francisco, CA. Revised 02/2019.

16. Privitera G, Luca T, Musso N, et al. In vitro antiproliferative effect of trastuzumab (Herceptin(®)) combined with cetuximab (Erbitux(®)) in a model of human non-small cell lung cancer expressing EGFR and HER2. Clinical And Experimental Medicine. 2016;16(2):161-168.

17. National Comprehensive Cancer Network (NCCN). Trastuzumab. NCCN Drugs and Biologics Compendium®. 2020.

18. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Trastuzumab. 2020.

19. Micromedex®Solutions Compendia. 2020. Trastuzumab.

20. Kanjinti (trastuzumab-anns) for injection, for intravenous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 10/2019.

21. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609.

22. Jung KH, Ataseven B, Verrill M, et al. Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study. Oncologist. 2018;23(10):1137-1143.

23. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 2017;317(1):37-47.

24. Micromedex®Solutions Compendia. 2020. Trastuzumab-anns.

25. Micromedex®Solutions Compendia. 2020. Trastuzumab-dkst.

26. Micromedex®Solutions Compendia. 2020. Trastuzumab-dttb.

27. Micromedex®Solutions Compendia. 2020. Trastuzumab-pkrb.

28. Micromedex®Solutions Compendia. 2020. Trastuzumab-qyyp.

29. Micromedex®Solutions Compendia. 2020. Trastuzumab and hyaluronidase-oysk

30. National Comprehensive Cancer Network (NCCN). Trastuzumab-anns. NCCN Drugs and Biologics Compendium®. 2020.

31. National Comprehensive Cancer Network (NCCN). Trastuzumab-dkst. NCCN Drugs and Biologics Compendium®. 2020.

32. National Comprehensive Cancer Network (NCCN). Trastuzumab-dttb. NCCN Drugs and Biologics Compendium®. 2020.

33. National Comprehensive Cancer Network (NCCN). Trastuzumab-pkrb. NCCN Drugs and Biologics Compendium®. 2020.

34. National Comprehensive Cancer Network (NCCN). Trastuzumab-qyyp. NCCN Drugs and Biologics Compendium®. 2020.

35. National Comprehensive Cancer Network (NCCN). Trastuzumab and hyaluronidase- oysk. NCCN Drugs and Biologics Compendium®. 2020.